Intraduodenal fecal microbiota transplantation ameliorates gut atrophy and cholestasis in a novel parenteral nutrition piglet model

Total parenteral nutrition (TPN) provides lifesaving nutritional support intravenously; however, it is associated with significant side effects. Given gut microbial alterations noted with TPN, we hypothesized that transferring fecal microbiota from healthy controls would restore gut-systemic signaling in TPN and mitigate injury. Using our novel ambulatory model (US Patent: US 63/136,165), 31 piglets were randomly allocated to enteral nutrition (EN), TPN only, TPN + antibiotics (TPN-A), or TPN + intraduodenal fecal microbiota transplant (TPN + FMT) for 14 days. Gut, liver, and serum were assessed through histology, biochemistry, and qPCR. Stool samples underwent 16 s rRNA sequencing. Permutational multivariate analysis of variance, Jaccard, and Bray-Curtis metrics were performed. Significant bilirubin elevation in TPN and TPN-A versus EN (<i>P</i> < 0.0001) was prevented with FMT. IFN-G, TNF-α, IL-β, IL-8, and lipopolysaccharide (LPS) were significantly higher in TPN (<i>P</i> = 0.009, P = 0.001, <i>P</i> = 0.043, <i>P</i> = 0.011, <i>P</i> < 0.0001), with preservation upon FMT. Significant gut atrophy by villous-to-crypt ratio in TPN (<i>P</i> < 0.0001) and TPN-A (<i>P</i> = 0.0001) versus EN was prevented by FMT (<i>P</i> = 0.426 vs. EN). Microbiota profiles using principal coordinate analysis demonstrated significant FMT and EN overlap, with the largest separation in TPN-A followed by TPN, driven primarily by Firmicutes and Fusobacteria. TPN-altered gut barrier was preserved upon FMT; upregulated cholesterol 7 α-hydroxylase and bile salt export pump in TPN and TPN-A and downregulated fibroblast growth factor receptor 4, EGF, farnesoid X receptor, and Takeda G Protein-coupled Receptor 5 (TGR5) versus EN was prevented by FMT. This study provides novel evidence of prevention of gut atrophy, liver injury, and microbial dysbiosis with intraduodenal FMT, challenging current paradigms into TPN injury mechanisms and underscores the importance of gut microbes as prime targets for therapeutics and drug discovery.<b>NEW & NOTEWORTHY</b> Intraduodenal fecal microbiota transplantation presents a novel strategy to mitigate complications associated with total parenteral nutrition (TPN), highlighting gut microbiota as a prime target for therapeutic and diagnostic approaches. These results from a highly translatable model provide hope for TPN side effect mitigation for thousands of chronically TPN-dependent patients.

Authors

Institutions

Publication Details

Journal
American Journal of Physiology-Gastrointestinal and Liver Physiology
Published
2024-08-20
DOI
https://doi.org/10.1152/ajpgi.00012.2024
Citations
2
Primary Topic
Clinical Nutrition and Gastroenterology
Type
article
Field-Weighted Citation Impact
0.62

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intraduodenal fecal microbiota transplantation ameliorates gut atrophy and cholestasis in a novel parenteral nutrition piglet model

Sherri Besmer, Ajay K. Jain, Aaron C. Ericsson, Chien‐Jung Lin et al.
2 citations
American Journal of Physiology-Gastrointestinal and Liver Physiology
Clinical Nutrition and Gastroenterology
0.62
article

Intraduodenal fecal microbiota transplantation ameliorates gut atrophy and cholestasis in a novel parenteral nutrition piglet model

Sherri Besmer, Ajay K. Jain, Aaron C. Ericsson, Chien‐Jung Lin, Christine Denton, Matthew McHale, Chelsea Hutchinson, Kamran Qureshi, Kento Kurashima, Mustafa Nazzal, Chandrashekhara Manithody, John A. Long, Yaşar Çalışkan, Ashlesha Bagwe, Jasmine Carter, Sonali Jain, Marzena Swiderska‐Syn, Miguel A. Guzmán, Shaurya Mehta
article en
2 citations

Abstract

Total parenteral nutrition (TPN) provides lifesaving nutritional support intravenously; however, it is associated with significant side effects. Given gut microbial alterations noted with TPN, we hypothesized that transferring fecal microbiota from healthy controls would restore gut-systemic signaling in TPN and mitigate injury. Using our novel ambulatory model (US Patent: US 63/136,165), 31 piglets were randomly allocated to enteral nutrition (EN), TPN only, TPN + antibiotics (TPN-A), or TPN + intraduodenal fecal microbiota transplant (TPN + FMT) for 14 days. Gut, liver, and serum were assessed through histology, biochemistry, and qPCR. Stool samples underwent 16 s rRNA sequencing. Permutational multivariate analysis of variance, Jaccard, and Bray-Curtis metrics were performed. Significant bilirubin elevation in TPN and TPN-A versus EN (<i>P</i> < 0.0001) was prevented with FMT. IFN-G, TNF-α, IL-β, IL-8, and lipopolysaccharide (LPS) were significantly higher in TPN (<i>P</i> = 0.009, P = 0.001, <i>P</i> = 0.043, <i>P</i> = 0.011, <i>P</i> < 0.0001), with preservation upon FMT. Significant gut atrophy by villous-to-crypt ratio in TPN (<i>P</i> < 0.0001) and TPN-A (<i>P</i> = 0.0001) versus EN was prevented by FMT (<i>P</i> = 0.426 vs. EN). Microbiota profiles using principal coordinate analysis demonstrated significant FMT and EN overlap, with the largest separation in TPN-A followed by TPN, driven primarily by Firmicutes and Fusobacteria. TPN-altered gut barrier was preserved upon FMT; upregulated cholesterol 7 α-hydroxylase and bile salt export pump in TPN and TPN-A and downregulated fibroblast growth factor receptor 4, EGF, farnesoid X receptor, and Takeda G Protein-coupled Receptor 5 (TGR5) versus EN was prevented by FMT. This study provides novel evidence of prevention of gut atrophy, liver injury, and microbial dysbiosis with intraduodenal FMT, challenging current paradigms into TPN injury mechanisms and underscores the importance of gut microbes as prime targets for therapeutics and drug discovery.<b>NEW & NOTEWORTHY</b> Intraduodenal fecal microbiota transplantation presents a novel strategy to mitigate complications associated with total parenteral nutrition (TPN), highlighting gut microbiota as a prime target for therapeutic and diagnostic approaches. These results from a highly translatable model provide hope for TPN side effect mitigation for thousands of chronically TPN-dependent patients.

American Journal of Physiology-Gastrointestinal and Liver PhysiologyVol. 327(5)
Saint Louis University (US), University of Missouri (US)
National Institutes of Health
Zero hunger
Openalex Percentile: Top 34%
Clinical Nutrition and Gastroenterology
0.62
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.